Uromedica, Inc.

Uromedica, Inc. is a Minnesota-based biotechnology startup established in 1997. Specializing in the development of minimally invasive, adjustable balloon devices for the treatment of stress urinary incontinence (SUI), the company manufactures ProACT and ACT. These innovative products have been successfully implanted in over 16,000 patients worldwide, delivering outstanding results. The company's flagship product, ProACT, received FDA approval for sale in the USA in November 2015, marking a significant milestone for Uromedica. Meanwhile, ACT is undergoing clinical trials for its female application and is not yet available for sale in the USA. Uromedica's implantable balloon therapies help address male and female stress urinary incontinence by providing long-term solutions that are incredibly safe and effective. The implantation procedure, which only takes approximately 30 minutes, offers patients a minimally invasive treatment option. Notably, the balloons can be adjusted post-operatively through a subcutaneous port and can be easily removed during a short office visit if necessary. In January 17, 2019, Uromedica received a $600.00K investment in its latest funding round, reflecting continued investor confidence in the company's pioneering medical technologies. Uromedica's dedication to addressing a prevalent medical issue in a minimally invasive manner positions the company as an innovative player in the biotechnology industry, with considerable potential for growth and further impactful contributions to the field of medical devices.